Fig. 6From: Transformative effect of a Humanitarian Program for individuals affected by rare diseases: building support systems and creating local expertisePercentage of individuals currently receiving enzyme replacement therapy in the program by time on treatment. Data as of May 2021. Note: humanitarian access to MPS II is limited to Sanofi Genzyme territory only. MPS, mucopolysaccharidosisBack to article page